CND Life Sciences is a company developing an accurate, evidence-based tool that helps confirm a diagnosis of synucleinopathy. It engages in the field of the detection, visualization, and quantification of protein deposition in cutaneous nerve fibers. CND Life Sciences develops technology that serves as an objective diagnostic tool to aid in the confirmation of synucleinopathy in patients with suspected Parkinson’s disease (PD), dementia with Lewy body (DLB), multiple system atrophy (MSA), or pure autonomic failure (PAF).